Famotidine
- Generic Name
- Famotidine
- Brand Names
- Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
- Drug Type
- Small Molecule
- Chemical Formula
- C8H15N7O2S3
- CAS Number
- 76824-35-6
- Unique Ingredient Identifier
- 5QZO15J2Z8
- Background
Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity to...
- Indication
Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.
...
- Associated Conditions
- Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions
- Associated Therapies
- -
A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05599828
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Dallas, Texas, United States
Gastrointestinal Dysmotility on Aspiration Risk
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05455359
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
- Conditions
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Leidos Life Sciences
- Registration Number
- NCT05085574
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Leidos Life Sciences
- Target Recruit Count
- 4
- Registration Number
- NCT05077969
- Locations
- 🇺🇸
Integrated Therapeutic Solutions USA, Inc., Dallas, Texas, United States
🇺🇸Integrated Therapeutic Solutions USA, Inc, Dearborn, Michigan, United States
🇺🇸Integrated Health Solutions USA, Inc., Atlanta, Georgia, United States
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
- Conditions
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Leidos Life Sciences
- Target Recruit Count
- 2000
- Registration Number
- NCT05077332
- Locations
- 🇺🇸
US02-04: Integrated Health Solutions, Miami, Florida, United States
Combined Antihistaminics Therapy in COVID 19 Patients
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 214
- Registration Number
- NCT05043350
- Locations
- 🇪🇬
Nasr City Insurance Hospital, Cairo, Egypt
A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT04949269
- Locations
- 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States
🇺🇸PPD Development, LP, Austin, Texas, United States
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT04941755
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Explore the Effect of Acid-reducing Agents
- Conditions
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04935112
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-01-11
- Target Recruit Count
- 8
- Registration Number
- NCT04918147
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Mayo Clinic: Pulmonary and Critical Care Medicine, Rochester, Minnesota, United States
🇺🇸Emory Healthcare, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.